Pricing

CRISPR Therapeutics AG (CRSP)

followers ·
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO: Samarth Kulkarni
Employees: 460
Web site: crisprtx.com
BAARERSTRASSE 14, ZUG, V8, CH-6300
6173154600
All 13F Filers Prior Change Hedge Funds 1 Prior Change
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available